Abivax (AAVXF) Other Operating Expenses (2024 - 2026)

Abivax has reported Other Operating Expenses for 3 years, with the latest figure at -$2.0 million in Q1 2026.

• On a quarterly basis, Other Operating Expenses fell 126.35% year-over-year to -$2.0 million in Q1 2026; TTM through Mar 2026 was -$7.1 million, a 87.03% increase from a year earlier, with the FY2025 full-year figure at -$6.0 million, up 4.97% from the prior year.
• Other Operating Expenses was -$2.0 million for Q1 2026 at Abivax, up from -$2.1 million in the prior quarter.
• The five-year high for Other Operating Expenses was -$762940.8 in Q2 2025, with the low at -$50.3 million in Q4 2024.
• Average Other Operating Expenses over 3 years is -$7.1 million, with a median of -$2.1 million recorded in 2025.
• The largest YoY upside for Other Operating Expenses was 95.79% in 2025 against a maximum downside of 129.5% in 2025.
• Over 3 years, Other Operating Expenses stood at -$50.3 million in 2024, then surged by 95.79% to -$2.1 million in 2025, then advanced by 3.45% to -$2.0 million in 2026.
• The last three Other Operating Expenses figures came in at -$2.0 million (Q1 2026), -$2.1 million (Q4 2025), and -$2.1 million (Q3 2025), per Business Quant data.